Muenster, Germany

Kastrup Horst


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kastrup Horst: Innovator in Inflammatory Disease Treatments

Introduction: Kastrup Horst is a prominent inventor based in Muenster, Germany, recognized for his significant contributions to the field of medical treatments for inflammatory diseases. With a firm grasp of pharmacological advancements, he has developed a novel patent that aims to enhance therapeutic options for patients suffering from respiratory and autoimmune conditions.

Latest Patents: Kastrup Horst holds a patent for a unique combination of anticholinergics, β2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids, and phosphodiesterase 4 inhibitors. This innovative invention is designed to treat inflammatory diseases, particularly focusing on respiratory issues like bronchial asthma and chronic obstructive pulmonary disease (COPD), as well as rheumatic or autoimmune diseases. His work demonstrates a comprehensive approach that utilizes multiple pharmacological agents to target inflammation effectively.

Career Highlights: Currently, Kastrup Horst is affiliated with Meda Pharma GmbH & Co. KG, a notable pharmaceutical company. His role at Meda Pharma underscores his commitment to advancing healthcare solutions. Throughout his career, he has been dedicated to research and development, striving to improve patient outcomes through innovative treatments.

Collaborations: In his endeavors, Kastrup has collaborated with esteemed colleagues such as Joachim Maus and Istvan Szelenyi. These partnerships reflect a spirit of teamwork and innovation, as they work collectively to push the boundaries of medical science and improve therapeutic strategies for inflammatory diseases.

Conclusion: Kastrup Horst stands out as a significant figure in the realm of medical innovation. His patent for the combination of various pharmacological agents presents a promising advancement in treating inflammatory diseases. With an ongoing commitment to research and collaboration at Meda Pharma, he continues to play a vital role in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…